AstraZeneca's Covid-19 antibody cocktail misses the mark in preventing symptoms post-exposure

As the field for monoclonal antibody treatments of Covid-19 grows more crowded, AstraZeneca has announced a study of its own cocktail AZD7442 did not meet its main goal of preventing symptomatic Covid-19.